Response's flu test:
This article was originally published in Clinica
Executive Summary
Response Biomedical has received US 510(k) clearance of its influenza A and B diagnostic, Flu A+B test. The rapid, point-of-care test will run on the Vancouver, Canada-based firm's new RAMP analyser platform, the RAMP 200. It will be marketed and sold exclusively worldwide by 3M Health Care as the 3M Rapid Detection Flu A+B Test. Response filed the 510(k) application in June 2007 (see Clinica No 1260, p 22). 3M Health Care plans to launch the test before the 2008-09 flu season in certain markets, and added it would be the first product sold in the US as part of its medical diagnostics platform.